Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.51 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 5/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403023 | 0.84 | TRPV4 (0.53) | KIF11TRPV4PTPN1PTPN2MEN1 | |
| SCHEMBL31026088 | 0.84 | TRPV4 (0.53) | KIF11TRPV4PTPN1PTPN2MEN1 | |
| SCHEMBL7569957 | 0.81 | TRPV4 (0.58) | KIF11TRPV4ARSLC22A12CYP3A4 | |
| SCHEMBL13525483 | 0.80 | CYP1A2 (0.44) | KIF11TRPV4PTPN1PTPN2MEN1 | |
| SCHEMBL30168580 | 0.78 | KIF11 (0.73) | KIF11TRPV4ARSLC22A12CYP3A4 | |
| SCHEMBL1727083 | 0.78 | KIF11 (0.73) | KIF11TRPV4ARSLC22A12CYP3A4 | |
| SCHEMBL5203682 | 0.78 | KIF11 (0.53) | KIF11TRPV4ARSLC22A12 | |
| SCHEMBL472402 | 0.76 | TRPV4 (0.53) | KIF11TRPV4NOTUMARSLC22A12 | |
| SCHEMBL8255777 | 0.76 | KIF11 (0.51) | KIF11TRPV4ARPDK2 | |
| SCHEMBL1724867 | 0.76 | KIF11 (0.51) | KIF11TRPV4ARSLC22A12CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101565369-B | Method for preparing 3-bromine-5-trifluoromethylbenzoic acid | JIANGSU KAIYUAN PHARMACEUTICAL CHEMICAL ENGINEERING CO LTD | 2012-10-03 | — | — | CN | claimed |
| CN-101565369-A | Method for preparing 3-bromine-5-trifluoromethylbenzoic acid | JIANGSU KAIYUAN PHARMACEUTICAL (CN) | 2009-10-28 | — | — | CN | claimed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2324032-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2324032-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20130317014-A1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. | 2013-11-28 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| CN-101565369-B | Method for preparing 3-bromine-5-trifluoromethylbenzoic acid | JIANGSU KAIYUAN PHARMACEUTICAL CHEMICAL ENGINEERING CO LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2324032-A2 | INHIBITORS OF BETA-SECRETASE | Vitae Pharmaceuticals, Inc. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| CN-101565369-A | Method for preparing 3-bromine-5-trifluoromethylbenzoic acid | JIANGSU KAIYUAN PHARMACEUTICAL (CN) | 2009-10-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | KIF11 4065/4885TRPV4 3668/4885PTPN1 3649/4885 |
| US-20130317014-A1 | INHIBITORS OF BETA-SECRETASE | BACE1, BACE2, APP | KIF11 4065/4885TRPV4 3668/4885PTPN1 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.